Latest by Pfizer, Inc.
Case Study of a Patient With Serious Hepatotoxicity in Maraviroc 2b/3 Trial Reported at Targeting HIV Entry -- 1st International Workshop
Bethesda, MD -- Howard Mayer, M.D. of Pfizer Global Research and Development presented today on a case of one patient with serious hepatotoxicity in the treatment naïve trial of the maraviroc phase 2b/3 program. Speaking at the "Targeting HIV Entry -...
Pfizer Discontinues Development of Capravirine, for HIV/AIDS
New London, CT -- Pfizer Inc. said today that it has discontinued clinical development on capravirine, a phase 2 HIV/AIDS drug in a class known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). Pfizer has been developing capravirine for pa...
New Nelfinavir Formulation Now Available for Patients With HIV
WHAT: Pfizer Inc. today announced that the 625 mg formulation of the protease inhibitor, VIRACEPT® (nelfinavir mesylate) is now available. VIRACEPT, in combination with other antiretroviral agents, is indicated for the treatment of HIV infection. Pfi...